Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Oncolytics Biotech (TSX:ONC) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10...
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherap...
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, ...
Pelareorep initiates a pro-inflammatory tumor microenvironment (TME) and induces innate and adaptive immune responsesNew analys...
ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patientsOngoing updates support ...
RBC Capital analyst Douglas Miehm maintains Oncolytics Biotech (TSX:ONC) with a Outperform and lowers the price target from ...
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), a leading clinical-stage company specializing in immunotherapy for oncology, ...
RBC Capital analyst Douglas Miehm reiterates Oncolytics Biotech (TSX:ONC) with a Outperform and maintains C$6 price target.
Cantor Fitzgerald analyst Louise Chen reiterates Oncolytics Biotech (TSX:ONC) with a Overweight.
